Literature DB >> 24424484

Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study.

Prue Cormie1, Daniel A Galvão, Nigel Spry, David Joseph, Dennis R Taaffe, Robert U Newton.   

Abstract

INTRODUCTION: Exercise may represent an effective adjunct therapy to current medical management strategies for maintaining functional independence and improving quality of life in cancer patients with bone metastatic disease. However, it has yet to be determined if there are any sustained effects following the completion of an exercise program by patients with bone metastases.
PURPOSE: The aim of this study is to determine whether a 3-month supervised resistance exercise program results in any sustained functional benefits in prostate and breast cancer patients with bone metastatic disease.
METHODS: Twenty men and women with bone metastatic disease secondary to prostate or breast cancer completed a 3-month supervised resistance exercise program followed by a 6-month observation period. Outcomes were assessed at baseline, post-exercise, and 6-month follow-up.
RESULTS: Fourteen participants completed the follow-up observation period. Significant improvements in physical function (4-6 %), physical activity levels (~160 min/week), lean mass (3-4 %), and quality of life (5-7 %) were observed at the completion of the exercise program. At the 6-month follow-up, significant improvements in ambulation (4 %), physical activity level (~105 min/week), whole body lean mass (2 %), and quality of life (13 %) remained.
CONCLUSIONS: An appropriately designed and supervised 3-month resistance exercise program may lead to significant improvements in functional ability, physical activity level, lean mass, and quality of life that remain 6 months after completion of the program in cancer patients with bone metastases. Future trials involving larger sample sizes are required to expand these preliminary findings.

Entities:  

Mesh:

Year:  2014        PMID: 24424484     DOI: 10.1007/s00520-013-2103-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  44 in total

1.  A new psychosocial screening instrument for use with cancer patients.

Authors:  J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis
Journal:  Psychosomatics       Date:  2001 May-Jun       Impact factor: 2.386

Review 2.  Nutrition and physical activity guidelines for cancer survivors.

Authors:  Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler
Journal:  CA Cancer J Clin       Date:  2012-04-26       Impact factor: 508.702

3.  Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy?

Authors:  Eduardo Ferriolli; Richard J E Skipworth; Paul Hendry; Angela Scott; Jacob Stensteth; Max Dahele; Lucy Wall; Carolyn Greig; Marie Fallon; Florian Strasser; Tom Preston; Kenneth C H Fearon
Journal:  J Pain Symptom Manage       Date:  2012-01-24       Impact factor: 3.612

4.  Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.

Authors:  G Hechmati; S Cure; A Gouépo; H Hoefeler; V Lorusso; D Lüftner; I Duran; C Garzon-Rodriguez; J Ashcroft; R Wei; P Ghelani; A Bahl
Journal:  J Med Econ       Date:  2013-03-15       Impact factor: 2.448

Review 5.  New and emerging therapies for bone metastases in genitourinary cancers.

Authors:  Philip J Saylor; Andrew J Armstrong; Karim Fizazi; Stephen Freedland; Fred Saad; Matthew R Smith; Bertrand Tombal; Kenneth Pienta
Journal:  Eur Urol       Date:  2012-11-23       Impact factor: 20.096

Review 6.  Epidemiology and consequences of sarcopenia.

Authors:  G Abellan van Kan
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

7.  Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases.

Authors:  P Cormie; R U Newton; N Spry; D Joseph; D R Taaffe; D A Galvão
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-08-06       Impact factor: 5.554

8.  In vivo tibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model.

Authors:  Maureen E Lynch; Daniel Brooks; Sunish Mohanan; Min Joon Lee; Praveen Polamraju; Kelsey Dent; Lawrence J Bonassar; Marjolein C H van der Meulen; Claudia Fischbach
Journal:  J Bone Miner Res       Date:  2013-11       Impact factor: 6.741

Review 9.  Zoledronic acid: a new parenteral bisphosphonate.

Authors:  Edward C Li; Lisa E Davis
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

Review 10.  Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

Authors:  Celestia S Higano
Journal:  Nat Clin Pract Urol       Date:  2008-01
View more
  29 in total

1.  Exercise Improves Physical Function and Mental Health of Brain Cancer Survivors: Two Exploratory Case Studies.

Authors:  Gregory T Levin; Kenneth M Greenwood; Favil Singh; Daphne Tsoi; Robert U Newton
Journal:  Integr Cancer Ther       Date:  2015-08-14       Impact factor: 3.279

2.  Exploring Diet, Physical Activity, and Quality of Life in Females with Metastatic Breast Cancer: A Pilot Study to Support Future Intervention.

Authors:  Patricia Sheean; Christopher Kabir; Ruta Rao; Kent Hoskins; Melinda Stolley
Journal:  J Acad Nutr Diet       Date:  2015-05-12       Impact factor: 4.910

3.  Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.

Authors:  Renée Bultijnck; Benedicte Deforche; Noëmi Borrey; Jörgen Van Bauwel; Maarten Lievens; Elke Rammant; Valérie Fonteyne; Karel Decaestecker; Adelheid Steyaert; Nicolaas Lumen; Piet Ost
Journal:  World J Urol       Date:  2020-02-01       Impact factor: 4.226

Review 4.  A Focused Review of Safety Considerations in Cancer Rehabilitation.

Authors:  Susan Maltser; Adrian Cristian; Julie K Silver; G Stephen Morris; Nicole L Stout
Journal:  PM R       Date:  2017-09       Impact factor: 2.298

Review 5.  High-intensity exercise interventions in cancer survivors: a systematic review exploring the impact on health outcomes.

Authors:  Kellie Toohey; Kate Pumpa; Andrew McKune; Julie Cooke; Stuart Semple
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-05       Impact factor: 4.553

6.  Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy.

Authors:  Nicolas H Hart; Robert U Newton; Nigel A Spry; Dennis R Taaffe; Suzanne K Chambers; Kynan T Feeney; David J Joseph; Andrew D Redfern; Tom Ferguson; Daniel A Galvão
Journal:  BMJ Open       Date:  2017-05-30       Impact factor: 2.692

Review 7.  Safety and feasibility of exercise interventions in patients with advanced cancer: a systematic review.

Authors:  Reginald Heywood; Alexandra L McCarthy; Tina L Skinner
Journal:  Support Care Cancer       Date:  2017-07-25       Impact factor: 3.603

8.  Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitators.

Authors:  Michelle Nadler; Daryl Bainbridge; Jennifer Tomasone; Oren Cheifetz; Rosalyn A Juergens; Jonathan Sussman
Journal:  Support Care Cancer       Date:  2017-03-03       Impact factor: 3.603

Review 9.  Searching for maintenance in exercise interventions for cancer survivors.

Authors:  Catherine M Jankowski; Marcia G Ory; Daniela B Friedman; Andrea Dwyer; Sarah A Birken; Betsy Risendal
Journal:  J Cancer Surviv       Date:  2014-08-08       Impact factor: 4.442

Review 10.  The Independent Effects of Strength Training in Cancer Survivors: a Systematic Review.

Authors:  Erik D Hanson; Chad W Wagoner; Travis Anderson; Claudio L Battaglini
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.